Compare AbCellera Biologics Inc (ABCL) vs Match Group Inc (MTCH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Match Group Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while Match Group Inc trades at $38.05 (market cap $9.14B). The key difference: Match Group Inc is far larger — about 3.9× AbCellera Biologics Inc's market cap, and Match Group Inc pays a 2.04% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MTCH | |
|---|---|---|
Market Cap | $2.35B | $9.14B |
Sector | Health | Media |
52-Week High | $8.12 | $39.18 |
52-Week Low | $2.78 | $28.90 |
Enterprise Value | $1.99B | $12.09B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
MTCH trades at $39.18, up 3.38% in the last session, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 73.8% gross margin and 18.83% net income margin, supported by positive cash flow trends. Recent news highlights a turnaround narrative, with Tinder stabilizing and Hinge driving growth.
Outlook is positive with a consensus price target of $41.63, implying 6.3% upside. Risks include high debt levels and user decline concerns. Analysts are bullish (53% buy ratings), but investors should monitor execution on growth initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
